In the past, many pharmaceutical companies treated compliance expenditures as vague year-end adjustments. As regulatory requirements become more granular, these costs are now a standard operational reality: academic activities, audits, traceability systems, and data documentation each require dedicated budgets, defined processes, and proper documentation.
First categorize, then manage.
We recommend categorizing expenditures into three types: (1) Regulatory Mandates, such as traceability and audit; (2) Business Support, such as academic promotion; and (3) Capability Building, such as compliance training and system development. Since each category follows a distinct decision logic, managing them together inevitably leads to cuts in the most critical spending.
II. From Expenses to Cost Items
Mandatory items should be allocated across product lines based on business volume to establish unit compliance costs. Support items should be initiated as projects with defined budgets and outcome evaluations. Investment items should be amortized annually. This approach transforms compliance spending from a black box into a transparent, comparable, and optimizable cost structure.
III. How to modify the assessment
If compliance costs are listed separately from sales expenses, the sales team lacks accountability. A better approach is to allocate compliance costs by product line and include them in gross margin assessments for each product, enabling business and compliance teams to align on a single metric.
IV. Records Are Assets
Complete records of approvals, contracts, invoices, and performance outcomes serve as a moat during audits and the basis for pricing. Time spent on documentation isn't an administrative burden—it's the infrastructure for risk-based pricing.
Compliance doesn't disappear when ignored—it just comes back at a higher cost. Addressing it in reports is the most cost-effective approach.